These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 6258218)

  • 1. All cis-5, 8, 11, 14, 17 eicosapentaenoic acid and triene prostaglandins: potential anti-thrombotic agents.
    Dyerberg J; Bang HO
    Scand J Clin Lab Invest; 1980; 40(7):589-93. PubMed ID: 6258218
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of all cis-5,8,11,14,17 eicosapentaenoic acid and PGH3 on platelet aggregation.
    Gryglewski RJ; Salmon JA; Ubatuba FB; Weatherly BC; Moncada S; Vane JR
    Prostaglandins; 1979 Sep; 18(3):453-78. PubMed ID: 531220
    [No Abstract]   [Full Text] [Related]  

  • 3. The effect of arachidonic- and eicosapentaenoic acid on the synthesis of prostacyclin-like material in human umbilical vasculature.
    Dyerberg J; Jørgensen KA
    Artery; 1980; 8(1):12-7. PubMed ID: 6252872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism underlying the inhibition of platelet aggregation by eicosapentaenoic acid and its metabolites.
    Needleman P; Sprecher H; Whitaker MO; Wyche A
    Adv Prostaglandin Thromboxane Res; 1980; 6():61-8. PubMed ID: 6247894
    [No Abstract]   [Full Text] [Related]  

  • 5. Prostacyclin (PGI2) and thromboxane A2 interaction in vivo. Regulation by aspirin and relationship with anti-thrombotic therapy.
    Korbut R; Moncada S
    Thromb Res; 1978 Sep; 13(3):489-500. PubMed ID: 369028
    [No Abstract]   [Full Text] [Related]  

  • 6. Eicosapentaenoic acid and platelet function in Japanese.
    Hirai A; Hamazaki T; Terano T; Nishikawa T; Tamura Y; Kamugai A; Jajiki J
    Lancet; 1980 Nov; 2(8204):1132-3. PubMed ID: 6107739
    [No Abstract]   [Full Text] [Related]  

  • 7. Dihomogammalinolenic acid (20:3 omega 6) is more anti-aggregatory than eicosapentaenoic (20:5 omega 3) in a platelet-endothelial cell mixture.
    Lagarde M; Burtin M; Dechavanne M; Sicard B; Coiffier B
    Prostaglandins Med; 1980 Mar; 4(3):177-83. PubMed ID: 6248913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thromboxane A2, prostacyclin and aspirin: effects on vascular tone and platelet aggregation.
    Smith JB; Araki H; Lefer AM
    Circulation; 1980 Dec; 62(6 Pt 2):V19-25. PubMed ID: 7002350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of dietary fatty acids, prostaglandins and related compounds on the role of platelets in thrombosis.
    Srivastava KC
    Biochem Exp Biol; 1980; 16(3):317-38. PubMed ID: 6268128
    [No Abstract]   [Full Text] [Related]  

  • 10. Pinane thromboxane A2: a TXA2 antagonist with antithrombotic properties.
    Aharony D; Smith JB; Smith EF; Lefer AM; Magolda RL; Nicolaou KD
    Adv Prostaglandin Thromboxane Res; 1980; 6():489-92. PubMed ID: 6992538
    [No Abstract]   [Full Text] [Related]  

  • 11. Modulation of human platelet function by prostacyclin and thromboxane A2.
    Gorman RR
    Fed Proc; 1979 Jan; 38(1):83-8. PubMed ID: 215465
    [No Abstract]   [Full Text] [Related]  

  • 12. Evidence for the mechanism by which eicosapentaenoic acid inhibits human platelet aggregation and secretion - implications for the prevention of vascular disease.
    Jakubowski JA; Ardlie NG
    Thromb Res; 1979; 16(1-2):205-17. PubMed ID: 388720
    [No Abstract]   [Full Text] [Related]  

  • 13. 9,11-epoxyiminoprosta-5,13-dienoic acid is a thromboxane A2 antagonist in human platelets.
    Fitzpatrick FA; Bundy GL; Gorman RR; Honohan T
    Nature; 1978 Oct; 275(5682):764-6. PubMed ID: 703845
    [No Abstract]   [Full Text] [Related]  

  • 14. Thromboxane A2 and the endoperoxides mediate canine platelet activation.
    Harris RH; Nichols R; Schmeling JW; Ramwell PW
    Thromb Res; 1981 Sep; 23(6):521-32. PubMed ID: 6798707
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of 11-week increases in dietary eicosapentaenoic acid on bleeding time, lipids, and platelet aggregation.
    Thorngren M; Gustafson A
    Lancet; 1981 Nov; 2(8257):1190-3. PubMed ID: 6118628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological interactions between prostacyclin and thromboxanes.
    Whittle BJ; Moncada S
    Br Med Bull; 1983 Jul; 39(3):232-8. PubMed ID: 6313114
    [No Abstract]   [Full Text] [Related]  

  • 17. Triene prostaglandins: prostaglandin D3 and icosapentaenoic acid as potential antithrombotic substances.
    Whitaker MO; Wyche A; Fitzpatrick F; Sprecher H; Needleman P
    Proc Natl Acad Sci U S A; 1979 Nov; 76(11):5919-23. PubMed ID: 230492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Membrane protein mediation of thromboxane A2-induced platelet aggregation.
    Kao KJ; Hagen PO; Pizzo SV
    Biochem Biophys Res Commun; 1980 Nov; 97(1):87-93. PubMed ID: 6779820
    [No Abstract]   [Full Text] [Related]  

  • 19. Reduction in blood viscosity by eicosapentaenoic acid.
    Kobayashi S; Hirai A; Terano T; Hamazaki T; Tamura Y; Kumagai A
    Lancet; 1981 Jul; 2(8239):197. PubMed ID: 6114257
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of the vascular responses to various prostanoic compounds in the puppy and adult dog.
    Fitzpatrick T; Harris R; Ramwell P; Kot P
    Adv Prostaglandin Thromboxane Res; 1980; 7():727-9. PubMed ID: 6989200
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.